The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Capecitabine as Adjuvant Treatment for Stage III Colon Cancer
Open accessAbstract
BACKGROUND: Intravenous bolus fluorouracil plus leucovorin is the standard adjuvant treatment for colon cancer. The oral fluoropyrimidine capecitabine is an established alternative to bolus fluorouracil plus leucovorin as first-line treatment for metastatic colorectal cancer. We evaluated capecitabine in the adjuvant setting. METHODS: We randomly assigned a total of 1987 patients with resected stage III colon cancer to receive either oral capecitabine (1004 patients) or bolus fluorouracil plus leucovorin (Mayo Clinic regimen; 983 patients) over a period of 24 weeks. The primary efficacy end point was at least equivalence in disease-free survival; the primary safety end point was the incidence of grade 3 or 4 toxic effects due to fluoropyrimidines. RESULTS: Disease-free survival in the capecitabine group was at least equivalent to that in the fluorouracil-plus-leucovorin group (in the intention-to-treat analysis, P<0.001 for the comparison of the upper limit of the hazard ratio with the noninferiority margin of 1.20). Capecitabine improved relapse-free survival (hazard ratio, 0.86; 95 percent confidence interval, 0.74 to 0.99; P=0.04) and was associated with significantly fewer adverse events than fluorouracil plus leucovorin (P<0.001). CONCLUSIONS: Oral capecitabine is an effective alternative to intravenous fluorouracil plus leucovorin in the adjuvant treatment of colon cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
André, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Zaninelli, M., Clingan, P., Bridgewater, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032709 · Cited by 3,689
Stewart, B. W., & Kleihues, P. (2003) · Cited by 2,386
Benson, A. B., Schrag, D., Somerfield, M. R., Cohen, A. M., Figueredo, A. T., Flynn, P. J., Krzyzanowska, M. K., Maroun, J., McAllister, P., Van Cutsem, E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.063 · Cited by 1,430
Self-citationMiwa, M., Ura, M., Nishida, M., Sawada, N., Ishikawa, T., Mori, K., Shimma, N., Umeda, I., & Ishitsuka, H. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00058-6 · Cited by 1,240
Efficacy of adjuvant fluorouracil and folinic acid in colon cancer
(1995) · The Lancet · doi:10.1016/s0140-6736(95)90696-7 · Cited by 1,066
Moertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Tangen, C. M., Ungerleider, J. S., Emerson, W. A., Tormey, D. C., Glick, J. H., et al. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-5-199503010-00001 · Cited by 925
Patient preferences for oral versus intravenous palliative chemotherapy.
Liu, G., Franssen, E., Fitch, M. I., & Warner, E. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.110 · Cited by 919
Edwards, B. K., Howe, H. L., Ries, L. A. G., Thun, M. J., Rosenberg, H. M., Yancik, R., Wingo, P. A., Jemal, A., & Feigal, E. G. (2002) · Cancer · doi:10.1002/cncr.10593 · Cited by 880
O'Connell, M. J., Mailliard, J. A., Kahn, M. J., Macdonald, J. S., Haller, D. G., Mayer, R. J., & Wieand, H. S. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.246 · Cited by 585
Sch�ller, J., Cassidy, J., Dumont, E., Roos, B., Banken, L., Mori, K., Reigner, B., Utoh, M., Weidekamm, E., & Durston, S. (2000) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050043 · Cited by 534
Self-citation
Cited by
Japanese Society for Cancer of the Colon and Rectum, Watanabe, T., Muro, K., Ajioka, Y., Hashiguchi, Y., Ito, Y., Saito, Y., Hamaguchi, T., Ishida, H., Ishiguro, M., et al. (2018) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1101-6 · Cited by 2,467
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
Cunningham, D., Starling, N., Rao, S., Iveson, T., Nicolson, M., Coxon, F., Middleton, G., Daniel, F., Oates, J., & Norman, A. R. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa073149 · Cited by 2,285
Hashiguchi, Y., Muro, K., Saito, Y., Ito, Y., Ajioka, Y., Hamaguchi, T., Hasegawa, K., Hotta, K., Ishida, H., Ishiguro, M., et al. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01485-z · Cited by 1,922
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
Masuda, N., Lee, S.-J., Ohtani, S., Im, Y.-H., Lee, E.-S., Yokota, I., Kuroi, K., Im, S.-A., Park, B.-W., Kim, S.-B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612645 · Cited by 1,888
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Schmoll, H. J., Van Cutsem, E., Stein, A., Valentini, V., Glimelius, B., Haustermans, K., Nordlinger, B., van de Velde, C. J., Balmana, J., Regula, J., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds236 · Cited by 1,510
Self-citationAdjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study
QUASAR Collaborative Group (2007) · The Lancet · doi:10.1016/s0140-6736(07)61866-2 · Cited by 1,437
Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Labianca, R., Nordlinger, B., Beretta, G. D., Mosconi, S., Mandalà, M., Cervantes, A., & Arnold, D. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt354 · Cited by 1,404
Self-citationCunningham, D., Atkin, W., Lenz, H.-J., Lynch, H. T., Minsky, B., Nordlinger, B., & Starling, N. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60353-4 · Cited by 1,351
Primrose, J. N., Fox, R. P., Palmer, D. H., Malik, H. Z., Prasad, R., Mirza, D., Anthony, A., Corrie, P., Falk, S., Finch-Jones, M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30915-x · Cited by 1,273
Duration of adjuvant chemotherapy for stage III colon cancer
Grothey, A., Sobrero, A. F., Shields, A. F., Yoshino, T., Paul, J., Taieb, J., Souglakos, J., Shi, Q., Kerr, R., Labianca, R., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713709 · Cited by 1,092
Kuebler, J. P., Wieand, H. S., O'Connell, M. J., Smith, R. E., Colangelo, L. H., Yothers, G., Petrelli, N. J., Findlay, M. P., Seay, T. E., Atkins, J. N., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2974 · Cited by 1,056
Cassidy, J., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9898 · Cited by 862
Self-citationHaller, D. G., Tabernero, J., Maroun, J., de Braud, F., Price, T., Van Cutsem, E., Hill, M., Gilberg, F., Rittweger, K., & Schmoll, H.-J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.6297 · Cited by 784
Self-citationEngstrom, P. F., Arnoletti, J. P., Benson, A. B., Chen, Y.-J., Choti, M. A., Cooper, H. S., Covey, A., Dilawari, R. A., Early, D. S., Enzinger, P. C., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0056 · Cited by 683
Pathways of Colorectal Carcinogenesis
Nguyen, L. H., Goel, A., & Chung, D. C. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.08.059 · Cited by 606
Breugom, A. J., Swets, M., Bosset, J.-F., Collette, L., Sainato, A., Cionini, L., Glynne-Jones, R., Counsell, N., Bastiaannet, E., van den Broek, C. B. M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71199-4 · Cited by 574
de Gramont, A., Van Cutsem, E., Schmoll, H.-J., Tabernero, J., Clarke, S., Moore, M. J., Cunningham, D., Cartwright, T. H., Hecht, J. R., Rivera, F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70509-0 · Cited by 529
Hofheinz, R.-D., Wenz, F., Post, S., Matzdorff, A., Laechelt, S., Hartmann, J. T., Müller, L., Link, H., Moehler, M., Kettner, E., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70116-x · Cited by 509
Systemic Treatment of Colorectal Cancer
Wolpin, B. M., & Mayer, R. J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.098 · Cited by 504
Chau, I., Brown, G., Cunningham, D., Tait, D., Wotherspoon, A., Norman, A. R., Tebbutt, N., Hill, M., Ross, P. J., Massey, A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.4875 · Cited by 474
Papamichael, D., Audisio, R. A., Glimelius, B., de Gramont, A., Glynne-Jones, R., Haller, D., Köhne, C.-H., Rostoft, S., Lemmens, V., Mitry, E., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu253 · Cited by 471
Zhang, M., Xiao, B., Wang, H., Han, M. K., Zhang, Z., Viennois, E., Xu, C., & Merlin, D. (2016) · Molecular Therapy · doi:10.1038/mt.2016.159 · Cited by 456
Engstrom, P. F., Arnoletti, J. P., Benson, A. B., Chen, Y.-J., Choti, M. A., Cooper, H. S., Covey, A., Dilawari, R. A., Early, D. S., Enzinger, P. C., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0057 · Cited by 439
Labianca, R., Beretta, G. D., Kildani, B., Milesi, L., Merlin, F., Mosconi, S., Pessi, M. A., Prochilo, T., Quadri, A., Gatta, G., et al. (2010) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2010.01.010 · Cited by 409
Breugom, A. J., van Gijn, W., Muller, E. W., Berglund, Å., van den Broek, C. B. M., Fokstuen, T., Gelderblom, H., Kapiteijn, E., Leer, J. W. H., Marijnen, C. A. M., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu560 · Cited by 391
Colorectal cancer: From prevention to personalized medicine
Binefa, G. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i22.6786 · Cited by 382
A Review of the Evolution of Systemic Chemotherapy in the Management of Colorectal Cancer
Gustavsson, B., Carlsson, G., Machover, D., Petrelli, N., Roth, A., Schmoll, H.-J., Tveit, K.-M., & Gibson, F. (2015) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2014.11.002 · Cited by 381
Punt, C. J. A., Buyse, M., Kohne, C.-H., Hohenberger, P., Labianca, R., Schmoll, H. J., Pahlman, L., Sobrero, A., & Douillard, J.-Y. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm024 · Cited by 379
Böckelman, C., Engelmann, B. E., Kaprio, T., Hansen, T. F., & Glimelius, B. (2015) · Acta Oncologica · doi:10.3109/0284186x.2014.975839 · Cited by 367
Dank, M., Zaluski, J., Barone, C., Valvere, V., Yalcin, S., Peschel, C., Wenczl, M., Goker, E., Cisar, L., Wang, K., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn166 · Cited by 343
Self-citationPersonalizing Colon Cancer Adjuvant Therapy: Selecting Optimal Treatments for Individual Patients
Dienstmann, R., Salazar, R., & Tabernero, J. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.0213 · Cited by 343
Labianca, R., Nordlinger, B., Beretta, G. D., Brouquet, A., & Cervantes, A. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq168 · Cited by 340
Self-citationLembersky, B. C., Wieand, H. S., Petrelli, N. J., O'Connell, M. J., Colangelo, L. H., Smith, R. E., Seay, T. E., Giguere, J. K., Marshall, M. E., Jacobs, A. D., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7498 · Cited by 328
Adjuvant Treatment of Colorectal Cancer
Wolpin, B. M., Meyerhardt, J. A., Mamon, H. J., & Mayer, R. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.3.168 · Cited by 306
Schmoll, H.-J., Cartwright, T., Tabernero, J., Nowacki, M. P., Figer, A., Maroun, J., Price, T., Lim, R., Van Cutsem, E., Park, Y.-S., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1075 · Cited by 298
Self-citationAndré, T., Meyerhardt, J., Iveson, T., Sobrero, A., Yoshino, T., Souglakos, I., Grothey, A., Niedzwiecki, D., Saunders, M., Labianca, R., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30527-1 · Cited by 297
Self-citationSchmoll, H.-J., Tabernero, J., Maroun, J., de Braud, F., Price, T., Van Cutsem, E., Hill, M., Hoersch, S., Rittweger, K., & Haller, D. G. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.9107 · Cited by 291
Self-citationS3-Leitlinie „Kolorektales Karzinom” – Aktualisierung 2008
Schmiegel, W., Reinacher-Schick, A., Arnold, D., Graeven, U., Heinemann, V, Porschen, R., Riemann, J., Rödel, C., Sauer, R., Wieser, M., et al. (2008) · Zeitschrift für Gastroenterologie · doi:10.1055/s-2008-1027726 · Cited by 274
McCleary, N. J., Meyerhardt, J. A., Green, E., Yothers, G., de Gramont, A., Van Cutsem, E., O'Connell, M., Twelves, C. J., Saltz, L. B., Haller, D. G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.6638 · Cited by 271
Self-citationDíaz-Rubio, E., Tabernero, J., Gómez-España, A., Massutí, B., Sastre, J., Chaves, M., Abad, A., Carrato, A., Queralt, B., Reina, J. J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.8467 · Cited by 268
Self-citationAdams, R. A., Meade, A. M., Seymour, M. T., Wilson, R. H., Madi, A., Fisher, D., Kenny, S. L., Kay, E., Hodgkinson, E., Pope, M., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70102-4 · Cited by 264
Prognostic and Predictive Molecular Biomarkers for Colorectal Cancer: Updates and Challenges
Koncina, E., Haan, S., Rauh, S., & Letellier, E. (2020) · Cancers · doi:10.3390/cancers12020319 · Cited by 259
Okines, A. F. C., Norman, A. R., McCloud, P., Kang, Y.-K., & Cunningham, D. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp047 · Cited by 258
Rosmarin, D., Palles, C., Church, D., Domingo, E., Jones, A., Johnstone, E., Wang, H., Love, S., Julier, P., Scudder, C., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.1857 · Cited by 256
Potential Regional Differences for the Tolerability Profiles of Fluoropyrimidines
Haller, D. G., Cassidy, J., Clarke, S. J., Cunningham, D., Van Cutsem, E., Hoff, P. M., Rothenberg, M. L., Saltz, L. B., Schmoll, H.-J., Allegra, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2090 · Cited by 252
Self-citationGastro-intestinal toxicity of chemotherapeutics in colorectal cancer: The role of inflammation
Lee, C. S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i14.3751 · Cited by 224
Xiao, B., Han, M. K., Viennois, E., Wang, L., Zhang, M., Si, X., & Merlin, D. (2015) · Nanoscale · doi:10.1039/c5nr04831a · Cited by 152
Bos, A. C. R. K., van Erning, F. N., van Gestel, Y. R. B. M., Creemers, G. J. M., Punt, C. J. A., van Oijen, M. G. H., & Lemmens, V. E. P. P. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.08.016 · Cited by 128
Malesci, A., Bianchi, P., Celesti, G., Basso, G., Marchesi, F., Grizzi, F., Di Caro, G., Cavalleri, T., Rimassa, L., Palmqvist, R., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1342918 · Cited by 124
“ropyrimidines improve 5-year survival rates by 10–15%, an additional 4–6% being contributed by their combination with oxaliplatin.(1-3) Even among patients receiving adjuvant therapy, one third still progresses to metastatic disease,(4-6) a rate not improved by biologic agents.”
BackgroundBalancing the efficacy and toxicity of chemotherapy in colorectal cancer
Braun, M. S., & Seymour, M. T. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834010388342 · Cited by 100
Cassidy, J., Saltz, L., Twelves, C., Van Cutsem, E., Hoff, P., Kang, Y., Saini, J. P., Gilberg, F., & Cunningham, D. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr031 · Cited by 90
Self-citationMaking sense of adjuvant chemotherapy in colorectal cancer
Chan, G. H. J., & Chee, C. E. (2019) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2019.06.03 · Cited by 82
Bender, U., Rho, Y. S., Barrera, I., Aghajanyan, S., Acoba, J., & Kavan, P. (2019) · Current Oncology · doi:10.3747/co.26.5605 · Cited by 36
Role of Real-World Evidence in Informing Cancer Care: Lessons from Colorectal Cancer
Batra, A., & Cheung, W. Y. (2019) · Current Oncology · doi:10.3747/co.26.5625 · Cited by 31
Metadata
- Authors
- Twelves, C., Wong, A., Nowacki, M. P., Abt, M., Burris, H., Carrato, A., Cassidy, J., Cervantes, A., Fagerberg, J., Georgoulias, V., Husseini, F., Jodrell, D., Koralewski, P., Kröning, H., Maroun, J., Marschner, N., McKendrick, J., Pawlicki, M., Rosso, R., Schüller, J., Seitz, J.-F., Stabuc, B., Tujakowski, J., Van Hazel, G., Zaluski, J., & Scheithauer, W.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-06-30
- Volume
- 352
- Issue
- 26
- Pages
- 2696-2704
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2146161922
- Cited by
- 1,248
- References
- 21
- FWCI
- 34.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.